shigella sonnei strain 53g
Cell therapyexperimental
Clinical trial activity
3 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 12, 2016 (NCT02816346)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Shigella sonneiImmunity, active
Shigella sonnei immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05959616 | Phase 1 | Mar 1, 2024 | Johns Hopkins University, PATH, United States Army, United States Navy, University of Oxford, Wellcome Trust |
| NCT04992520 | Phase 1 | Feb 21, 2022 | Department of Defense, Johns Hopkins University, PATH |
| NCT02816346 | Phase 1 | Sep 12, 2016 | Department of Defense, PATH, University of Cincinnati |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| PATH | Academic/Hospital | 3 | 2 | 1 | 2016 |
| Department of Defense | Government | 2 | 0 | 1 | 2016 |
| Johns Hopkins University | Academic/Hospital | 2 | 0 | 1 | 2022 |
| United States Army | Government | 1 | 0 | 1 | 2024 |
| United States Navy | Government | 1 | 0 | 1 | 2024 |
| University of Cincinnati | Academic/Hospital | 1 | 0 | 1 | 2016 |
| University of Oxford | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Wellcome Trust | Academic/Hospital | 1 | 0 | 1 | 2024 |
8 organizations
Page 1 / 1